mytilitol | 564-92-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: mytilitol
• 英文别名: Mytilit
• CAS: 564-92-1
• 化学式: C₇H₁₄O₆
• 分子量: 194.185
• InChiKey: AJGYLNFUYLRZFR-VQPJZGIOSA-N

物化性质

• 熔点：
  259 °C
• 沸点：
  287.4±40.0 °C(Predicted)
• 密度：
  1.818±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.44
• 重原子数：
  13.0
• 可旋转键数：
  0.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  121.38
• 氢给体数：
  6.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  4-壬基苯甲酰氯 、 mytilitol 在 三氟乙酸 作用下， 以39%的产率得到Hexa-O-(4-nonylbenzoyl)mytilit
  参考文献：
  名称：

  Kohne, Bernd; Praefcke, Klaus; Stephan, Werner, Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie, 1985, vol. 40, # 7, p. 981 - 986

  摘要：

  DOI：
• 作为产物：
  描述：

  在 sodium methylate 、 异丁胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 水 为溶剂， 反应 40.0h， 生成 mytilitol
  参考文献：
  名称：

  磺酸盐保护基。O-和C-甲基化肌醇的合成：d-和l-肌醇，d-和l-laminitol，Mytilitol和scyllo-肌醇甲醚

  摘要：

  D-和L- ononitol，d-和l- laminitol的合成，mytilitol和鲨肌醇甲醚从开始肌肉肌醇中描述。一个或两个的肌肉肌醇1,3,5-原甲酸羟基被保护的甲苯磺酸盐。这些单或二甲苯磺酸盐用作制备O-和C-甲基肌醇的关键中间体。外消旋2,4-二- ö甲苯磺酰肌肉肌醇1,3,5-原甲酸酯得到解决作为其非对映体camphanates。使用磺酸根基团保护肌醇羟基导致O-和C-甲基肌醇的总产率的显着提高。

  DOI：

  10.1016/j.tet.2005.02.073

文献信息

• Syntheses of Optically Active 2,3,6-Tri-<i>O</i>-benzyl-D-<i>myo</i>-inositol, Laminitol, and Mytilitol from D-Glucose
  作者：Ken-ichi Sato、Masayuki Bokura、Makoto Taniguchi

  DOI：10.1246/bcsj.67.1633

  日期：1994.6

  2,3,6-Tri-O-benzyl-d-myo-inositol, which is a key intermediate of d-inositol 1,4,5-triphosphate, was synthesized from d-glucose without performing any optical resolution by utilizing C2 symmetry. Laminitol and mytilitol were also synthesized from d-glucose via the same key intermediate, 1d-(1,3/2,4)-tetra-O-benzyl-2-C-methyl-5-cyclohexene-1,2,3,4-tetrol.

  2,3,6-三-O-苄基-d-肌醇，作为d-肌醇1,4,5-三磷酸的关键中间体，通过利用C2对称性，未进行任何光学拆分直接从d-葡萄糖合成得到。通过对同一关键中间体，即1d-(1,3/2,4)-四-O-苄基-2-C-甲基-5-环己烯-1,2,3,4-四醇的应用，还从d-葡萄糖合成了羊齿醇和贻贝醇。
• Recherches dans la série des cyclites VII. Sur la cyclite des moules (mytilite) et sur quelques substances voisines
  作者：Théodore Posternak

  DOI：10.1002/hlca.19440270156

  日期：——
• 1-FLUORO-1-DEOXY-SCYLLO-INOSITOL FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Waratah Pharmaceuticals, Inc.

  公开号：EP1940373B1

  公开（公告）日：2015-05-06
• Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
  申请人：Cruz Antonio

  公开号：US20070111970A1

  公开（公告）日：2007-05-17

  Inositol derivatives are described that are represented by the structural formula I wherein X is a radical of scyllo-inositol wherein one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl, or carboxamide and the other of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl, or pharmaceutically acceptable salts thereof. The compounds, compositions comprising same and methods using same are described for use in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence.
• SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE
  申请人：Cruz Antonio

  公开号：US20090170957A1

  公开（公告）日：2009-07-02

  Scyllo-Inositol derivatives represented by structural formula II are described, wherein at least one and not more than five of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, ammo, lmmo, azido, thiol, thioalkyl, thioaryl, mtro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl or carbamide, or pharmaceutically acceptable salts thereof. Said derivatives and compositions comprising the same are useful in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence.